About Metascreen

Metascreen, a comprehensive metabolic screening test currently designed for newborn babies, is the first of Cordlife Group’s new product and service offerings in diagnostics, as the Group transforms into a consumer healthcare company catering to the mother and child segment.

Compared to other similar screening services that require blood for testing, Metascreen is a non-invasive and painless test that can screen for more than 100 inborn errors of metabolism using urine samples of newborns. With the early critical information on the health status of their child provided by Metascreen, parents can now better safeguard their child’s health.

The metabolic screening tests offered under the brand, Metascreen, will be conducted and analysed by Cordlife (Hong Kong) Ltd., a company committed to providing early and accurate detection of metabolic disorders. Cordlife (Hong Kong) Ltd., a subsidiary of Cordlife, has a quality management system in place to ensure maximum accuracy of screening results.

Unlike blood specimen collection, collecting urine specimen is a non-invasive procedure which will not cause any harm or discomfort to your baby

Metascreen Testing Platform

Where is your Metascreen technology from?

We use a gas-chromatography mass spectrometry (GC-MS) technology manufactured by Shimadzu, Japan. After processing the urine specimen through GC-MS, we analyse the GC-MS data using proprietary planar bioinformatics first developed by Japanese researchers. The planar bioinformatics makes use of multiple analytes (metabolites) from more than one biochemical (metabolic) pathway to identify a single metabolic disorder. This means that the results would be more reliable and accurate than traditional technology using mass tandem spectrometry (MS-MS) because MS-MS only uses about 1 or 2 analyte profiles for each disorder, and often, the same analyte profile is used for multiple disorders.

Metascreen gas-chromatography mass spectrometry